TriangleStandard of Care HDR Brachytherapy (NCT07751159)
Standard of Care HDR Brachytherapy trial for Prostate Cancer Patients (NCT07751159). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people with nonmetastatic prostate cancer at unfavorable intermediate, high, or very high risk. Their radiation oncologist must consider them suitable for both study approaches.
The idea: patients are randomized to a high-dose-rate brachytherapy boost plus stereotactic body radiation therapy, or stereotactic body radiation alone. Researchers test whether the simpler approach reduces urinary symptoms while studying the balance between cancer control and side effects. The comparison measures urinary symptoms at three months.
This phase 2 study plans 126 patients. Daniel Gorovets leads at Memorial Sloan Kettering; seven US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.